Masahiro Yamamoto

Yamagata, 9909585, Japan

Last Updated: 09/26/2026

Save publications for later
Sign Up
Not sure about your diagnosis?
Check Your Symptoms
Found 23 publications

Gemcitabine Cooperates with Everolimus to Inhibit the Growth of and Sensitize Malignant Meningioma Cells to Apoptosis Induced by Navitoclax, an Inhibitor of Anti-Apoptotic BCL-2 Family Proteins.

Gemcitabine Cooperates with Everolimus to Inhibit the Growth of and Sensitize Malignant Meningioma Cells to Apoptosis Induced by Navitoclax, an Inhibitor of Anti-Apoptotic BCL-2 Family Proteins.

Journal: Cancers
Published: February 02, 2022

Gemcitabine radiosensitization primes irradiated malignant meningioma cells for senolytic elimination by navitoclax.

Gemcitabine radiosensitization primes irradiated malignant meningioma cells for senolytic elimination by navitoclax.

Journal: Neuro-oncology advances
Published: November 12, 2021

Targeting Folate Metabolism Is Selectively Cytotoxic to Glioma Stem Cells and Effectively Cooperates with Differentiation Therapy to Eliminate Tumor-Initiating Cells in Glioma Xenografts.

Targeting Folate Metabolism Is Selectively Cytotoxic to Glioma Stem Cells and Effectively Cooperates with Differentiation Therapy to Eliminate Tumor-Initiating Cells in Glioma Xenografts.

Journal: International journal of molecular sciences
Published: September 27, 2021

Dexamethasone Sensitizes Cancer Stem Cells to Gemcitabine and 5-Fluorouracil by Increasing Reactive Oxygen Species Production through NRF2 Reduction.

Dexamethasone Sensitizes Cancer Stem Cells to Gemcitabine and 5-Fluorouracil by Increasing Reactive Oxygen Species Production through NRF2 Reduction.

Journal: Life (Basel, Switzerland)
Published: July 15, 2021

Lurasidone Sensitizes Cancer Cells to Osimertinib by Inducing Autophagy and Reduction of Survivin.

Lurasidone Sensitizes Cancer Cells to Osimertinib by Inducing Autophagy and Reduction of Survivin.

Journal: Anticancer research
Published: May 31, 2021

Roles for hENT1 and dCK in gemcitabine sensitivity and malignancy of meningioma.

Roles for hENT1 and dCK in gemcitabine sensitivity and malignancy of meningioma.

Journal: Neuro-oncology
Published: February 08, 2021

Inhibition of the Lipid Droplet-Peroxisome Proliferator-Activated Receptor α Axis Suppresses Cancer Stem Cell Properties.

Inhibition of the Lipid Droplet-Peroxisome Proliferator-Activated Receptor α Axis Suppresses Cancer Stem Cell Properties.

Journal: Genes
Published: October 30, 2020

Therapeutic targeting of pancreatic cancer stem cells by dexamethasone modulation of the MKP-1-JNK axis.

Therapeutic targeting of pancreatic cancer stem cells by dexamethasone modulation of the MKP-1-JNK axis.

Journal: The Journal of biological chemistry
Published: July 14, 2020

Inhibition of Retinoblastoma Cell Growth by CEP1347 Through Activation of the P53 Pathway.

Inhibition of Retinoblastoma Cell Growth by CEP1347 Through Activation of the P53 Pathway.

Journal: Anticancer research
Published: June 17, 2020

Doxazosin, a Classic Alpha 1-Adrenoceptor Antagonist, Overcomes Osimertinib Resistance in Cancer Cells via the Upregulation of Autophagy as Drug Repurposing.

Doxazosin, a Classic Alpha 1-Adrenoceptor Antagonist, Overcomes Osimertinib Resistance in Cancer Cells via the Upregulation of Autophagy as Drug Repurposing.

Journal: Biomedicines
Published: June 16, 2020

Spironolactone, a Classic Potassium-Sparing Diuretic, Reduces Survivin Expression and Chemosensitizes Cancer Cells to Non-DNA-Damaging Anticancer Drugs.

Spironolactone, a Classic Potassium-Sparing Diuretic, Reduces Survivin Expression and Chemosensitizes Cancer Cells to Non-DNA-Damaging Anticancer Drugs.

Journal: Cancers
Published: August 26, 2019

Brexpiprazole Reduces Survivin and Reverses EGFR Tyrosine Kinase Inhibitor Resistance in Lung and Pancreatic Cancer.

Brexpiprazole Reduces Survivin and Reverses EGFR Tyrosine Kinase Inhibitor Resistance in Lung and Pancreatic Cancer.

Journal: Anticancer research
Published: August 08, 2019
Showing 1-12 of 23

Last Updated: 09/26/2026